Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
暂无分享,去创建一个
R. Califf | J. McMurray | H. White | C. Granger | L. Køber | A. Maggioni | S. Al‐Khatib | E. Velazquez | K. Pieper | Yi Zhou | Kent R Nilsson | E. Lewis
[1] Michael Weis,et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.
[2] C. Frampton,et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. , 2008, European heart journal.
[3] A. Camm,et al. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .
[4] L. Newby,et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation , 2008, Heart.
[5] David W. Hosmer,et al. Applied Survival Analysis: Regression Modeling of Time-to-Event Data , 2008 .
[6] Jane A. Linderbaum,et al. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Wr , 2008, Journal of the American College of Cardiology.
[7] Kevin L. Thomas,et al. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. , 2008, American heart journal.
[8] S. Solomon,et al. Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction ☆ , 2006, European journal of heart failure.
[9] J. Parner,et al. Raised Plasma Aldosterone and Natriuretic Peptides in Atrial Fibrillation , 2006, Cardiology.
[10] M. Davidian,et al. Smoothing Spline‐Based Score Tests for Proportional Hazards Models , 2006, Biometrics.
[11] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[12] M. Gold,et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. , 2006, The American journal of cardiology.
[13] L. Wallentin,et al. Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-Term Outcome: A Prospective Cohort Study From the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) , 2005, Circulation.
[14] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[15] Shu-lin Wu,et al. Prophylactic Use of an Implantable Cardioverter-defibrillator after Acute Myocardial Infarction , 2005 .
[16] Eric Fain,et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. , 2004, The New England journal of medicine.
[17] Lippincott Williams Wilkins,et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .
[18] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[19] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[20] H. Crijns,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.
[21] H. Crijns,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .
[22] A L Waldo,et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.
[23] H. Doval,et al. Class III antiarrhythmic agents in cardiac failure: lessons from clinical trials with a focus on the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). , 1999, The American journal of cardiology.
[24] R. Califf,et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.
[25] S. Connolly,et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.
[26] A. Camm,et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.
[27] Bertram Pitt,et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.
[28] P C Deedwania,et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.
[29] H. Katayama,et al. Contrast sonography for detection of vesicoureteral reflux , 1994, The Lancet.
[30] Stroke Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study , 1994, The Lancet.
[31] H. White,et al. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .
[32] Lippincott Williams Wilkins,et al. Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.
[33] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.
[34] Silvia G. Priori,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .